YI Oct 2024 2.500 call
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.3000 |
| Strike | 2.50 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.1000 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 272 |
PR Newswire111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility
111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced that the Company has entered into a strategic direct supply partnership (the "Partnership") with Beijing Scrianen Pharmaceutical Co., Ltd. ("Scrianen"), a comprehensive pharmaceutical enterprise that integrates research and development, production and marketing.
PR Newswire111, Inc. Announces First Quarter 2024 Unaudited Financial Results
111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2024.
PR Newswire111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow
111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024, before the U.S. market opens on Thursday, May 23, 2024.
